Gene insertion startup Tome Biosciences stops lab work as CEO shifts focus to deal talks
Tome Biosciences, a high-profile gene editing startup spun out of MIT, is halting its lab work and looking to sell itself or find a partner …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
